Technology evaluation: gemtuzumab ozogamicin, Celltech Group. (Q34183275)

scientific article

Language	Label	Description	Also known as
English	Technology evaluation: gemtuzumab ozogamicin, Celltech Group.	scientific article

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

review article

1 reference

stated in

Europe PubMed Central

title

Technology evaluation: gemtuzumab ozogamicin, Celltech Group (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

author name string

I Niculescu-Duvaz

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

publication date

1 December 2000

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

published in

Current Opinion in Molecular Therapeutics

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

volume

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

issue

6

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

page(s)

691-696

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

retrieved

5 November 2019

Identifiers

PubMed publication ID

11249747

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11249747

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11249747%20AND%20SRC:MED&resulttype=core&format=json

Technology evaluation: gemtuzumab ozogamicin, Celltech Group. (Q34183275)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Technology evaluation: gemtuzumab ozogamicin, Celltech Group. (Q34183275)

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Navigation menu

Search